Cargando…

Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression

BACKGROUND: Prostate cancer (PC) is a common noncutaneous malignancy in men. The incidence of PC is increasing at an alarming rate across the globe. Progression of PC is associated with elevated levels of interleukin-8 (IL-8) and cyclooxygenase-2 (COX-2) in malignant cells. Overexpression of these p...

Descripción completa

Detalles Bibliográficos
Autores principales: Setty Balakrishnan, Anand, Nathan, Abel Arul, Kumar, Mukesh, Ramamoorthy, Sudhakar, Ramia Mothilal, Sathish Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448731/
https://www.ncbi.nlm.nih.gov/pubmed/28593171
http://dx.doi.org/10.1016/j.prnil.2017.03.002
_version_ 1783239613405462528
author Setty Balakrishnan, Anand
Nathan, Abel Arul
Kumar, Mukesh
Ramamoorthy, Sudhakar
Ramia Mothilal, Sathish Kumar
author_facet Setty Balakrishnan, Anand
Nathan, Abel Arul
Kumar, Mukesh
Ramamoorthy, Sudhakar
Ramia Mothilal, Sathish Kumar
author_sort Setty Balakrishnan, Anand
collection PubMed
description BACKGROUND: Prostate cancer (PC) is a common noncutaneous malignancy in men. The incidence of PC is increasing at an alarming rate across the globe. Progression of PC is associated with elevated levels of interleukin-8 (IL-8) and cyclooxygenase-2 (COX-2) in malignant cells. Overexpression of these players is accompanied by chronic inflammation, increased angiogenesis, proliferation, migration, and inhibition of apoptosis. Moreover, their elevated circulating levels promote the disease progression from androgen-dependent to androgen-independent state. Thus, inhibiting the expression of IL-8 and COX-2 would be a promising target in the development of PC therapeutics. In this study, we investigated the inhibitory effects of Withania somnifera extract on highly metastatic, androgen-independent prostate cancer cell line (PC3). Additionally, we compared the real-time expression of IL-8 and COX-2 in prostate tissue samples. MATERIALS AND METHODS: The cell viability and cytotoxicity of W. somnifera extract in PC3 cells was quantified colorimetrically by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and lactate dehydrogenase leakage assay, respectively. Hematoxylin and eosin staining for histological examination, trypan blue, and acridine orange dyes to enumerate apoptotic and live cells, quantitative real-time polymerase chain reaction to determine the expression and flow cytometry to study the cell cycle analysis were used. RESULTS: We observed a significant decrease in the cell viability with a half-maximal inhibitory concentration (IC(50)) of 10 μg/mL. The expression levels of IL-8 and COX-2 in prostate tissue samples and in PC3 cells were predominantly high; however, the lowest dose of W. somnifera significantly inhibited the enhanced expression of IL-8 and COX-2 in PC3 cells in 24 hours. Furthermore, W. somnifera extract (10 μg/mL) irreversibly arrested the cell cycle in G(2)/M phase, which was evident from the rapid accumulation of PC3 cells significantly. CONCLUSION: Our results indicate that inherent metastatic and selective inhibitory potential of W. somnifera against PC. W. somnifera may be a good therapeutic agent in addition to the existing drugs for PC. Further studies with more prostate tissue samples are warranted.
format Online
Article
Text
id pubmed-5448731
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Asian Pacific Prostate Society
record_format MEDLINE/PubMed
spelling pubmed-54487312017-06-07 Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression Setty Balakrishnan, Anand Nathan, Abel Arul Kumar, Mukesh Ramamoorthy, Sudhakar Ramia Mothilal, Sathish Kumar Prostate Int Original Article BACKGROUND: Prostate cancer (PC) is a common noncutaneous malignancy in men. The incidence of PC is increasing at an alarming rate across the globe. Progression of PC is associated with elevated levels of interleukin-8 (IL-8) and cyclooxygenase-2 (COX-2) in malignant cells. Overexpression of these players is accompanied by chronic inflammation, increased angiogenesis, proliferation, migration, and inhibition of apoptosis. Moreover, their elevated circulating levels promote the disease progression from androgen-dependent to androgen-independent state. Thus, inhibiting the expression of IL-8 and COX-2 would be a promising target in the development of PC therapeutics. In this study, we investigated the inhibitory effects of Withania somnifera extract on highly metastatic, androgen-independent prostate cancer cell line (PC3). Additionally, we compared the real-time expression of IL-8 and COX-2 in prostate tissue samples. MATERIALS AND METHODS: The cell viability and cytotoxicity of W. somnifera extract in PC3 cells was quantified colorimetrically by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and lactate dehydrogenase leakage assay, respectively. Hematoxylin and eosin staining for histological examination, trypan blue, and acridine orange dyes to enumerate apoptotic and live cells, quantitative real-time polymerase chain reaction to determine the expression and flow cytometry to study the cell cycle analysis were used. RESULTS: We observed a significant decrease in the cell viability with a half-maximal inhibitory concentration (IC(50)) of 10 μg/mL. The expression levels of IL-8 and COX-2 in prostate tissue samples and in PC3 cells were predominantly high; however, the lowest dose of W. somnifera significantly inhibited the enhanced expression of IL-8 and COX-2 in PC3 cells in 24 hours. Furthermore, W. somnifera extract (10 μg/mL) irreversibly arrested the cell cycle in G(2)/M phase, which was evident from the rapid accumulation of PC3 cells significantly. CONCLUSION: Our results indicate that inherent metastatic and selective inhibitory potential of W. somnifera against PC. W. somnifera may be a good therapeutic agent in addition to the existing drugs for PC. Further studies with more prostate tissue samples are warranted. Asian Pacific Prostate Society 2017-06 2017-03-16 /pmc/articles/PMC5448731/ /pubmed/28593171 http://dx.doi.org/10.1016/j.prnil.2017.03.002 Text en © 2017 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Setty Balakrishnan, Anand
Nathan, Abel Arul
Kumar, Mukesh
Ramamoorthy, Sudhakar
Ramia Mothilal, Sathish Kumar
Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression
title Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression
title_full Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression
title_fullStr Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression
title_full_unstemmed Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression
title_short Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression
title_sort withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448731/
https://www.ncbi.nlm.nih.gov/pubmed/28593171
http://dx.doi.org/10.1016/j.prnil.2017.03.002
work_keys_str_mv AT settybalakrishnananand withaniasomniferatargetsinterleukin8andcyclooxygenase2inhumanprostatecancerprogression
AT nathanabelarul withaniasomniferatargetsinterleukin8andcyclooxygenase2inhumanprostatecancerprogression
AT kumarmukesh withaniasomniferatargetsinterleukin8andcyclooxygenase2inhumanprostatecancerprogression
AT ramamoorthysudhakar withaniasomniferatargetsinterleukin8andcyclooxygenase2inhumanprostatecancerprogression
AT ramiamothilalsathishkumar withaniasomniferatargetsinterleukin8andcyclooxygenase2inhumanprostatecancerprogression